Dr. Matt Segar Named Winner for AHA Samuel A. Levine Early Career Clinical Investigator Award
Matthew Segar, MD, MS, a Texas Heart Institute Cardiology Fellow, has been selected as the winner of the Samuel A. Levine Early Career Clinical Investigator Award competition by the American Heart Association’s Council on Clinical Cardiology (CLCD) for his presentation “Development and Validation of a Phenomapping Tool to Identify Patients With Diuretic Resistance in Acute Decompensated Heart Failure: A Multi-Cohort Analysis.”
The Samuel A. Levine Early Career Clinical Investigator Award recognizes and rewards innovative clinical research by early career investigators and trainees and promotes careers in clinical cardiovascular investigation. The award is named for Samuel Albert Levine, MD, an American cardiologist. Dr. Levine was a pioneer in the treatment of coronary thrombosis.
Dr. Segar’s work investigates diuretic resistance, which is commonly encountered in clinical practice but remains difficult to predict in patients.
His presentation is a continuation of the research he performed during his residency training at the University of Texas Southwestern Medical Center in Dallas in collaboration with Ambarish Pandey, MD, MS.
Drs. Segar, Pandey, and their co-authors developed a phenomapping tool to help identify patients with acute decompensated heart failure who had a high probability of having diuretic resistance. Using machine learning, they identified key biological factors underlying diuretic resistance in this heart failure population.
His research team is the first to identify a diuretic-resistant phenogroup and validate a diuretic resistance clinical risk score to better identify high-risk patients.
Dr. Segar presented his research at the American Heart Association’s 2022 Scientific Sessions on Saturday, November 5.
Follow the conversation at #AHA22
Early Career Awards – Professional Heart Daily